Moderna (MRNA) reiterates it expects 2026 revenue growth of 15% to 25% (prev. 10%), and is on track to achieve approximately 10ppts of gross margin expansion in 2026, excluding the litigation settlement charge

Moderna (MRNA) reiterates it expects 2026 revenue growth of 15% to 25% (prev. 10%), and is on track to achieve approximately 10ppts of gross margin expansion in 2026, excluding the litigation settlement charge.

Reiterations with an upward revision to prior guidance tend to matter more than fresh initiations, because they signal the company's own confidence has firmed between communications rather than merely holding the line; the pattern in comparable cases is that the market weighs the raised floor against how much of the improvement is already in consensus. The two components here behave differently: the revenue growth revision speaks to the top line trajectory of the commercial vaccine franchise, while the margin expansion target is a cost-structure story, and the explicit exclusion of the litigation settlement charge is the kind of carve-out that invites scrutiny of the gap between adjusted and reported figures. Guidance of this sort from a single-product-weighted biotech has historically been hostage to seasonal respiratory demand, contract timing and regulatory label decisions, so the follow-ons are the next print's phasing disclosure, any update on pipeline readouts that underpin the outer-year growth claim, and whether the margin bridge is attributed to volume, mix or manufacturing efficiency. Prior episodes of guidance raises from this issuer have seen the initial reaction fade when subsequent delivery lagged the framing, which puts weight on execution evidence over the coming quarters rather than the headline numbers themselves.